GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onward Medical NV (XBRU:ONWD) » Definitions » ROCE %
中文

Onward Medical NV (XBRU:ONWD) ROCE % : -62.69% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Onward Medical NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Onward Medical NV's annualized ROCE % for the quarter that ended in Jun. 2023 was -62.69%.


Onward Medical NV ROCE % Historical Data

The historical data trend for Onward Medical NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onward Medical NV ROCE % Chart

Onward Medical NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROCE %
Get a 7-Day Free Trial -115.16 -76.44 -96.80 -51.72 -38.21

Onward Medical NV Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
ROCE % Get a 7-Day Free Trial Premium Member Only -92.96 -57.92 -32.84 -44.21 -62.69

Onward Medical NV ROCE % Calculation

Onward Medical NV's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-32.023/( ( (104.796 - 5.542) + (76.593 - 8.221) )/ 2 )
=-32.023/( (99.254+68.372)/ 2 )
=-32.023/83.813
=-38.21 %

Onward Medical NV's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-37.56/( ( (76.593 - 8.221) + (59.027 - 7.577) )/ 2 )
=-37.56/( ( 68.372 + 51.45 )/ 2 )
=-37.56/59.911
=-62.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Onward Medical NV  (XBRU:ONWD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Onward Medical NV ROCE % Related Terms

Thank you for viewing the detailed overview of Onward Medical NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Onward Medical NV (XBRU:ONWD) Business Description

Traded in Other Exchanges
Address
High Tech Campus 32, Noord-Braban, Eindhoven, NH, NLD, NL-5656 AE
Onward Medical NV is a medical technology company developing and commercializing therapies to enable functional recovery for people with spinal cord injury. It has developed two programmable neurostimulation platforms: an implantable system, ARCIM, and a non-invasive, transcutaneous system, ARCEX. The company has selected the United states and four European markets: Germany, France, the UK and the Netherlands to create a customer base.

Onward Medical NV (XBRU:ONWD) Headlines

No Headlines